|Dr. Yuval Cohen||CEO & Director||827.32k||N/A||1975|
|Mr. Sean F. Moran CPA, M.B.A., CPA, MBA||Chief Financial Officer||528k||N/A||1958|
|Dr. Barbara White||Head of Research & Chief Medical Officer||579.48k||N/A||1950|
|Ted Jenkins||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Scott Constantine||Sr. Director & Head of Clinical Operations||N/A||N/A||N/A|
|Mr. Craig Stuart Millian M.B.A.||Chief Commercial Officer||N/A||N/A||1968|
|Mr. Dylan Wenke||Head of Bus. Devel.||N/A||N/A||N/A|
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 9.